Briefly noted: V Ajmera et al. Clin Gastroenterol Hepatol 2018; 16: 1511-20. This study with 285 participants showed that modest alcohol consumption was associated with a lower odds of NASH resolution on biopsy over 4 years compared with no alcohol consumption (OR 0.32). The associated editorial (pg 1404-6) provides a table with 8 studies that reveal conflicting results on this issue.
My take (borrowed from editorial): “Clinicians should not recommend modest drinking” as a way of improving liver health.
Related review article:D Fuster, JH Samet. “Alcohol Use in Patients with Chronic Liver Disease” NEJM 2018; 379: 1251-61. For NAFLD (and all chronic liver disease): “abstinence should be the goal.”
Related blog posts:
Lake Moraine, Banff
A recent NY Times article highlights the end of a renowned food-scientist Brian Wansink’s career at Cornell which “came to an unceremonious end. On Sept. 20. The university announced that a yearlong investigation had found that he committed “academic misconduct in his research and scholarship, including misreporting of research data,” and that he had tendered his resignation.” This commentary highlights other problems with nutrition studies: More Evidence That Nutrition Studies Don’t Always Add Up
My take: Nutrition studies are difficult –having academic misconduct is going to further undermine the credibility of these studies.
C Ma et al. Clin Gastroenterol Hepaatol 2018; 16: 1407-19. This study examined endpoints in randomized controlled trials (RCTs) of Crohn’s disease. Key finding: Among 116 included RCTs (n=27,263 patients), there were 38 unique definitions of clinical response or remission and 32 definitions of loss of response. The most common endpoint was CD activity index.
RP Hirten et al. Clin Gastroenterol Hepatol 2018; 16: 1374-84. This review examines the topic of combining biologics in inflammatory bowel disease. Currently, there is little data in IBD. From studies completed in rheumatology and dermatology, there are some safety concerns. One current study, the EXPLORER study, which is a phase 4 open label trial evaluating the use of vedolizumab in combination with adalimumab and methotrexate, will provide some useful information. With regard to safety, gut-specific anti-integrin therapies are likely to be safer in combination than other biologic therapies.
RJ Colman et al. Inflamm Bowel Dis 2018; 24: 2135-41. This systematic review and meta-analysis which included 14 eligible studies showed that the pooled clinical remission rate with methotrexate monotherapy for pediatric Crohn’s disease was 57.7% at 3-6 months and 37.1% at 1 year.
AA Wren et al. Inflamm Bowel Dis 2018; 24: 2093-2105. This study with 93,668 patients in a cohort from Truven MarketScan Database (2007-2015) identified a high rate of opioid therapy usage in U.S. adolescents and young adults (15-29 year olds). Annual prevalence of chronic opioid use was 9.3% in 2007 and peaked at 12.2% in 2011. In 2015, the prevalence dropped to 10.8%. Overall, 18.2% had received chronic opioid therapy. Among the 2503 with chronic opioid usage who were followed longitudinally, 30.5% received opioids for 2 years and 5.3% for 4 years. The associated editorial (ME Kuenzig, EI Benchimol, pg 2140-5) note that these prevalence data may underestimate the true rate of opioid use due to the case definition of IBD used when analyzing the administrative data.
Lake Moraine, Banff
A recent study (M Geserick et al. NEJM 2018; 379: 1303-12) performed a prospective and retrospective analysis of a population-based sample of 51,505 German children to examine BMI in early childhood and risk of sustained obesity.
- Most normal weight adolescents had a normal weight throughout childhood
- Half (53%) of the obese adolescents had been overweight or obese from 5 years of age onward
- Almost 90% of children who were obese at 3 years of age were overweight or obese in adolescence
- Among obese adolescents, the most rapid weight gain had occurred between 2 and 6 years of age
My take: We are losing the childhood obesity battle at very young ages.
Abstract and Link to 1:32 Quick Summary: Acceleration of BMI in Early Childhood
It is well-recognized that there is a high rate of burnout and even suicides among physicians. The concern regarding mental health extends to medical students. According to a recent commentary (JF Karp, AS Levine. NEJM 2018; 1196-8), “despite entering medical school with relatively good mental health, medical students become depressed, burned out, and suicidal at alarming rates.” This is thought to be due to “demanding schedules, cost, and stigma” to obtain mental health services.
The editorial advocates for medical students: “Working closely with the physician-services divisions of large hospital systems may help schools and hospitals leverage resources and provide shared opportunities to improve the care of students, trainees, and faculty and staff physicians.”
Related blog posts on burnout:
Frpm NEJM twitter feed
A recent review (ME McCabe, CK Dilly. Clin Gastroenterol Hepatol 2018; 16: 1389-92) provides useful information on bile reflux gastritis.
The authors note that bile reflux gastritis is “increasingly found in individuals without prior gastric surgery, a problem termed ‘primary biliary reflux.'”
- Most often bile reflux gastritis occurs due to prior surgery affecting pylorus, dysmotility, after cholecystectomy (due to loss of bile reservoir), and after biliary sphincterotomy (due to increased biliary flow).
- Suggested treatments (Figure 5) -are limited by lack of evidence but the following are recommended by the authors: remove offending medications (eg. agents that affect peristalsis) –>proton pump inhibitors –>ursodeoxycholic acid –>sucralfate –>combination therapy –>surgical diversion of bile (generally reserved in those with surgically-induced bile reflux)
A recent prospective study (D Petroff et al. Clin Gastroenterol Hepatol 2018; 16: 1442-49) with 345 pediatric patients with biopsy-proven celiac disease (CD) examined serologic response to a gluten-free diet (GFD) between 2012-2015.
- Mean TTG IgA concentration decreased 14-fold after 3 months of a GFD. The study assay used kits from EUROIMMUN.
- TTG IgA remained above 1-fold ULN in 83.8% and above 10-fold ULN in 26.6%.
- Deamidated gliadin IgA (DGL IgA) decreased in the vast majority but did not distinguish response of GFD from random fluctuations.
- The authors note that symptoms improved in most on GFD, but short-term response could reflect “regression to the mean…for a considerable share” as symptoms improved in the non-GFD group as well.
In their discussion, the authors reference a large study (n=487) which showed mean normalization of TTG IgA of ~400 days; longer times were noted in those with type 1 diabetes and higher baseline values.
My take: This study, while showing that TTG IgA levels improve after 3 months of a GFD, helps solidify my opinion that in those who are improving, followup serology could be obtained later. My practice is to have followup serology after 6 months of a GFD in the majority of patients.
Related blog posts:
Lake Moraine, Banff